INTRODUCTION

Robert Li founded LTZ Therapeutics in 2021, assuming the role of Chief Executive Officer (CEO). Robert is a seasoned drug developer with over 15 years of industry experience in translational research and development within the therapeutic areas of immunology, oncology, and cancer immunology. He has held multiple leadership roles, including biotech executive, cross-functional team lead, and immunology therapeutic area lead in safety assessment, at global pharmaceutical companies such as Bristol-Myers Squibb, Genentech, and Vir Biotechnology. He has led and supported the achievement of critical developmental milestones for more than 10 small and large molecules, including IND filings, pivotal trials, NDA/BLA submissions, and global regulatory interactions. He is frequently invited as a speaker, chair, and/or panelist at international conferences, including the AACR-FDA workshop, CDE workshop, SOT annual meeting, BioSafe annual meeting, Bispecific Summit, JP Morgan Regional Expert Meeting, and the BiG Meeting, among others.

Dr. Li received his Ph.D. in Immunotoxicology from the University of Toronto, followed by postdoctoral training at Hoffmann-La Roche. In addition to his responsibilities at LTZ Therapeutics, he served as the President of the SOT Biotechnology Specialty Section from 2021 to 2022, where he contributed to the advancement of the field. He is also the recipient of the SOT Outstanding Young Immunotoxicologist award in 2017 and the Outstanding Young Investigator in Biotechnology award in 2018.